Industry Research Reports

Home > Reports > Chemical & Material > Global Pazopanib API Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Global Pazopanib API Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Industry: Chemical & Material

Published Date: 2025-11-09

Pages: 99 Pages

Report ld: 5402052

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Pazopanib API Market Size(US$)

CAGR 2025-2031

7.9%

Market Size,2031

USD 2,553

Million

Market Snapshot

Market Size in 2025 (Value)

US$ 1,618 million

Market Forecast in 2031(Value)

US$ 2,553 million

CAGR

7.9%

Years Considered

2020-2031

Base Year

2025

Forecast Period

2025-2031

Source: Secondary research, interviews with experts, and QYResearch analysis

The global Pazopanib API market size was US$ 1510 million in 2024 and is forecast to a readjusted size of US$ 2553 million by 2031 with a CAGR of 7.9% during the forecast period 2025-2031.

Pazopanib is an anticancer medication that belongs to the class of drugs known as kinase inhibitors. It is primarily used for the treatment of advanced renal cell carcinoma (kidney cancer) and soft tissue sarcoma.

API stands for Active Pharmaceutical Ingredient, which is the biologically active component in a drug product that produces the intended therapeutic effect. Pazopanib API refers to the pure form of pazopanib that is used as the active ingredient in the manufacturing of pazopanib-based medications.

Pazopanib API is typically produced through chemical synthesis, which involves multi-step processes to obtain the desired compound in its pure form. This pure active ingredient is then used as a starting material for formulating tablets, capsules, or other drug dosage forms.

The global pazopanib API market refers to the market for the active pharmaceutical ingredient (API) of pazopanib, a medication used for the treatment of certain types of cancer. Pazopanib is an oral, multi-kinase inhibitor that works by inhibiting the growth of blood vessels within tumors, thereby suppressing their progression.

The market for pazopanib API is driven by several factors, including the increasing incidence of cancer worldwide, the growing demand for targeted therapies, and advancements in pharmaceutical research and development. Pazopanib is primarily indicated for the treatment of advanced renal cell carcinoma (kidney cancer), as well as soft tissue sarcoma.

Geographically, the market for pazopanib API is global, with significant demand in regions such as North America, Europe, and Asia-Pacific. North America, particularly the United States, holds a prominent share due to a high prevalence of renal cell carcinoma, well-established healthcare infrastructure, and robust drug development capabilities. Europe is another significant market, driven by factors such as increasing awareness about targeted therapies and the presence of major pharmaceutical companies. Asia-Pacific is witnessing rapid growth, attributed to factors such as a rising incidence of cancer, improving healthcare infrastructure, and increasing investments in research and development.

Key players in the global pazopanib API market include pharmaceutical companies involved in API manufacturing, contract research organizations (CROs), and contract manufacturing organizations (CMOs). These companies focus on the development and production of high-quality pazopanib API, complying with regulatory standards and ensuring the availability of a reliable supply chain.

However, challenges in the pazopanib API market include potential side effects and adverse reactions associated with the medication, high costs of targeted therapies, and competition from generic alternatives. Additionally, the market dynamics for APIs are influenced by factors such as the patent expiration of branded drugs and the emergence of biosimilars.

In summary, the global pazopanib API market is driven by factors such as the increasing incidence of cancer, demand for targeted therapies, and advancements in pharmaceutical research. North America currently leads the market, but Asia-Pacific is witnessing rapid growth. Key players in the market continue to focus on the development and production of high-quality pazopanib API to meet the demand for cancer treatment and improve patient outcomes.

The global Pazopanib API market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.

MARKET SEGMENTATION

By Company

Tecoland
FCDA
BIOBERRY
Abcr
Dr. Reddys Laboratories
Pharmaffiliates
Jigs Chemical Limited
MuseChem
Hairuichem
AlchemyPharm
Wuhan Fortuna Chemical
Shanghai Pharmaceutical Group Co
Shijiazhuang Dingmin Pharmaceutical Sciences
CR Pharmaceutical Group
Guangzhou Baiyunshan Pharmaceutical Group

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Min Purity Less Than 98%
Min Purity 98%-99%
Min Purity More Than 99%

Segment by Application

Research
Pharmaceutical
Others

biaoTi CHAPTER OUTLINE

Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).

Chapter 2: Quantitative analysis of Pazopanib API market size and growth potential at global, regional, and country levels.

Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).

Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Min Purity 98%-99% in China).

Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Pharmaceutical in India).

Chapter 6: Regional revenue breakdown by company, type, application and customer.

Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.

Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.

Chapter 9: Actionable conclusions and strategic recommendations.

WHY THIS REPORT

Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Pazopanib API value chain, addressing:

- Market entry risks/opportunities by region

- Product mix optimization based on local practices

- Competitor tactics in fragmented vs. consolidated markets

biaoTi QYRESEARCH'S STRENGTHS

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Report Overview

1.1 Study Scope

1.2 Market by Type

1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031

1.2.2 Min Purity Less Than 98%

1.2.3 Min Purity 98%-99%

1.2.4 Min Purity More Than 99%

1.3 Market by Application

1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031

1.3.2 Research

1.3.3 Pharmaceutical

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Pazopanib API Market Perspective (2020-2031)

2.2 Global Market Size by Region: 2020 VS 2024 VS 2031

2.3 Global Pazopanib API Revenue Market Share by Region (2020-2025)

2.4 Global Pazopanib API Revenue Forecast by Region (2026-2031)

2.5 Major Region and Emerging Market Analysis

2.5.1 North America Pazopanib API Market Size and Prospective (2020-2031)

2.5.2 Europe Pazopanib API Market Size and Prospective (2020-2031)

2.5.3 Asia-Pacific Pazopanib API Market Size and Prospective (2020-2031)

2.5.4 Latin America Pazopanib API Market Size and Prospective (2020-2031)

2.5.5 Middle East & Africa Pazopanib API Market Size and Prospective (2020-2031)

3 Breakdown Data by Type

3.1 Global Pazopanib API Historic Market Size by Type (2020-2025)

3.2 Global Pazopanib API Forecasted Market Size by Type (2026-2031)

3.3 Different Types Pazopanib API Representative Players

4 Breakdown Data by Application

4.1 Global Pazopanib API Historic Market Size by Application (2020-2025)

4.2 Global Pazopanib API Forecasted Market Size by Application (2026-2031)

4.3 New Sources of Growth in Pazopanib API Application

5 Competition Landscape by Players

5.1 Global Top Players by Revenue

5.1.1 Global Top Pazopanib API Players by Revenue (2020-2025)

5.1.2 Global Pazopanib API Revenue Market Share by Players (2020-2025)

5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

5.3 Players Covered: Ranking by Pazopanib API Revenue

5.4 Global Pazopanib API Market Concentration Analysis

5.4.1 Global Pazopanib API Market Concentration Ratio (CR5 and HHI)

5.4.2 Global Top 10 and Top 5 Companies by Pazopanib API Revenue in 2024

5.5 Global Key Players of Pazopanib API Head office and Area Served

5.6 Global Key Players of Pazopanib API, Product and Application

5.7 Global Key Players of Pazopanib API, Date of Enter into This Industry

5.8 Mergers & Acquisitions, Expansion Plans

6 Region Analysis

6.1 North America Market: Players, Segments and Downstream

6.1.1 North America Pazopanib API Revenue by Company (2020-2025)

6.1.2 North America Market Size by Type

6.1.2.1 North America Pazopanib API Market Size by Type (2020-2025)

6.1.2.2 North America Pazopanib API Market Share by Type (2020-2025)

6.1.3 North America Market Size by Application

6.1.3.1 North America Pazopanib API Market Size by Application (2020-2025)

6.1.3.2 North America Pazopanib API Market Share by Application (2020-2025)

6.1.4 North America Market Trend and Opportunities

6.2 Europe Market: Players, Segments and Downstream

6.2.1 Europe Pazopanib API Revenue by Company (2020-2025)

6.2.2 Europe Market Size by Type

6.2.2.1 Europe Pazopanib API Market Size by Type (2020-2025)

6.2.2.2 Europe Pazopanib API Market Share by Type (2020-2025)

6.2.3 Europe Market Size by Application

6.2.3.1 Europe Pazopanib API Market Size by Application (2020-2025)

6.2.3.2 Europe Pazopanib API Market Share by Application (2020-2025)

6.2.4 Europe Market Trend and Opportunities

6.3 Asia-Pacific Market: Players, Segments and Downstream

6.3.1 Asia-Pacific Pazopanib API Revenue by Company (2020-2025)

6.3.2 Asia-Pacific Market Size by Type

6.3.2.1 Asia-Pacific Pazopanib API Market Size by Type (2020-2025)

6.3.2.2 Asia-Pacific Pazopanib API Market Share by Type (2020-2025)

6.3.3 Asia-Pacific Market Size by Application

6.3.3.1 Asia-Pacific Pazopanib API Market Size by Application (2020-2025)

6.3.3.2 Asia-Pacific Pazopanib API Market Share by Application (2020-2025)

6.3.4 Asia-Pacific Market Trend and Opportunities

6.4 Latin America Market: Players, Segments and Downstream

6.4.1 Latin America Pazopanib API Revenue by Company (2020-2025)

6.4.2 Latin America Market Size by Type

6.4.2.1 Latin America Pazopanib API Market Size by Type (2020-2025)

6.4.2.2 Latin America Pazopanib API Market Share by Type (2020-2025)

6.4.3 Latin America Market Size by Application

6.4.3.1 Latin America Pazopanib API Market Size by Application (2020-2025)

6.4.3.2 Latin America Pazopanib API Market Share by Application (2020-2025)

6.4.4 Latin America Market Trend and Opportunities

6.5 Middle East & Africa Market: Players, Segments and Downstream

6.5.1 Middle East & Africa Pazopanib API Revenue by Company (2020-2025)

6.5.2 Middle East & Africa Market Size by Type

6.5.2.1 Middle East & Africa Pazopanib API Market Size by Type (2020-2025)

6.5.2.2 Middle East & Africa Pazopanib API Market Share by Type (2020-2025)

6.5.3 Middle East & Africa Market Size by Application

6.5.3.1 Middle East & Africa Pazopanib API Market Size by Application (2020-2025)

6.5.3.2 Middle East & Africa Pazopanib API Market Share by Application (2020-2025)

6.5.4 Middle East & Africa Market Trend and Opportunities

7 Key Players Profiles

7.1 Tecoland

7.1.1 Tecoland Company Details

7.1.2 Tecoland Business Overview

7.1.3 Tecoland Pazopanib API Introduction

7.1.4 Tecoland Revenue in Pazopanib API Business (2020-2025)

7.1.5 Tecoland Recent Development

7.2 FCDA

7.2.1 FCDA Company Details

7.2.2 FCDA Business Overview

7.2.3 FCDA Pazopanib API Introduction

7.2.4 FCDA Revenue in Pazopanib API Business (2020-2025)

7.2.5 FCDA Recent Development

7.3 BIOBERRY

7.3.1 BIOBERRY Company Details

7.3.2 BIOBERRY Business Overview

7.3.3 BIOBERRY Pazopanib API Introduction

7.3.4 BIOBERRY Revenue in Pazopanib API Business (2020-2025)

7.3.5 BIOBERRY Recent Development

7.4 Abcr

7.4.1 Abcr Company Details

7.4.2 Abcr Business Overview

7.4.3 Abcr Pazopanib API Introduction

7.4.4 Abcr Revenue in Pazopanib API Business (2020-2025)

7.4.5 Abcr Recent Development

7.5 Dr. Reddys Laboratories

7.5.1 Dr. Reddys Laboratories Company Details

7.5.2 Dr. Reddys Laboratories Business Overview

7.5.3 Dr. Reddys Laboratories Pazopanib API Introduction

7.5.4 Dr. Reddys Laboratories Revenue in Pazopanib API Business (2020-2025)

7.5.5 Dr. Reddys Laboratories Recent Development

7.6 Pharmaffiliates

7.6.1 Pharmaffiliates Company Details

7.6.2 Pharmaffiliates Business Overview

7.6.3 Pharmaffiliates Pazopanib API Introduction

7.6.4 Pharmaffiliates Revenue in Pazopanib API Business (2020-2025)

7.6.5 Pharmaffiliates Recent Development

7.7 Jigs Chemical Limited

7.7.1 Jigs Chemical Limited Company Details

7.7.2 Jigs Chemical Limited Business Overview

7.7.3 Jigs Chemical Limited Pazopanib API Introduction

7.7.4 Jigs Chemical Limited Revenue in Pazopanib API Business (2020-2025)

7.7.5 Jigs Chemical Limited Recent Development

7.8 MuseChem

7.8.1 MuseChem Company Details

7.8.2 MuseChem Business Overview

7.8.3 MuseChem Pazopanib API Introduction

7.8.4 MuseChem Revenue in Pazopanib API Business (2020-2025)

7.8.5 MuseChem Recent Development

7.9 Hairuichem

7.9.1 Hairuichem Company Details

7.9.2 Hairuichem Business Overview

7.9.3 Hairuichem Pazopanib API Introduction

7.9.4 Hairuichem Revenue in Pazopanib API Business (2020-2025)

7.9.5 Hairuichem Recent Development

7.10 AlchemyPharm

7.10.1 AlchemyPharm Company Details

7.10.2 AlchemyPharm Business Overview

7.10.3 AlchemyPharm Pazopanib API Introduction

7.10.4 AlchemyPharm Revenue in Pazopanib API Business (2020-2025)

7.10.5 AlchemyPharm Recent Development

7.11 Wuhan Fortuna Chemical

7.11.1 Wuhan Fortuna Chemical Company Details

7.11.2 Wuhan Fortuna Chemical Business Overview

7.11.3 Wuhan Fortuna Chemical Pazopanib API Introduction

7.11.4 Wuhan Fortuna Chemical Revenue in Pazopanib API Business (2020-2025)

7.11.5 Wuhan Fortuna Chemical Recent Development

7.12 Shanghai Pharmaceutical Group Co

7.12.1 Shanghai Pharmaceutical Group Co Company Details

7.12.2 Shanghai Pharmaceutical Group Co Business Overview

7.12.3 Shanghai Pharmaceutical Group Co Pazopanib API Introduction

7.12.4 Shanghai Pharmaceutical Group Co Revenue in Pazopanib API Business (2020-2025)

7.12.5 Shanghai Pharmaceutical Group Co Recent Development

7.13 Shijiazhuang Dingmin Pharmaceutical Sciences

7.13.1 Shijiazhuang Dingmin Pharmaceutical Sciences Company Details

7.13.2 Shijiazhuang Dingmin Pharmaceutical Sciences Business Overview

7.13.3 Shijiazhuang Dingmin Pharmaceutical Sciences Pazopanib API Introduction

7.13.4 Shijiazhuang Dingmin Pharmaceutical Sciences Revenue in Pazopanib API Business (2020-2025)

7.13.5 Shijiazhuang Dingmin Pharmaceutical Sciences Recent Development

7.14 CR Pharmaceutical Group

7.14.1 CR Pharmaceutical Group Company Details

7.14.2 CR Pharmaceutical Group Business Overview

7.14.3 CR Pharmaceutical Group Pazopanib API Introduction

7.14.4 CR Pharmaceutical Group Revenue in Pazopanib API Business (2020-2025)

7.14.5 CR Pharmaceutical Group Recent Development

7.15 Guangzhou Baiyunshan Pharmaceutical Group

7.15.1 Guangzhou Baiyunshan Pharmaceutical Group Company Details

7.15.2 Guangzhou Baiyunshan Pharmaceutical Group Business Overview

7.15.3 Guangzhou Baiyunshan Pharmaceutical Group Pazopanib API Introduction

7.15.4 Guangzhou Baiyunshan Pharmaceutical Group Revenue in Pazopanib API Business (2020-2025)

7.15.5 Guangzhou Baiyunshan Pharmaceutical Group Recent Development

8 Pazopanib API Market Dynamics

8.1 Pazopanib API Industry Trends

8.2 Pazopanib API Market Drivers

8.3 Pazopanib API Market Challenges

8.4 Pazopanib API Market Restraints

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Global Pazopanib API Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Global Pazopanib API Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 3. Global Market Pazopanib API Market Size (US$ Million) by Region:2020 VS 2024 VS 2031

Table 4. Global Pazopanib API Revenue (US$ Million) Market Share by Region (2020-2025)

Table 5. Global Pazopanib API Revenue Share by Region (2020-2025)

Table 6. Global Pazopanib API Revenue (US$ Million) Forecast by Region (2026-2031)

Table 7. Global Pazopanib API Revenue Share Forecast by Region (2026-2031)

Table 8. Global Pazopanib API Market Size by Type (2020-2025) & (US$ Million)

Table 9. Global Pazopanib API Revenue Market Share by Type (2020-2025)

Table 10. Global Pazopanib API Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 11. Global Pazopanib API Revenue Market Share by Type (2026-2031)

Table 12. Representative Players of Each Type

Table 13. Global Pazopanib API Market Size by Application (2020-2025) & (US$ Million)

Table 14. Global Pazopanib API Revenue Market Share by Application (2020-2025)

Table 15. Global Pazopanib API Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 16. Global Pazopanib API Revenue Market Share by Application (2026-2031)

Table 17. New Sources of Growth in Pazopanib API Application

Table 18. Global Pazopanib API Revenue by Players (2020-2025) & (US$ Million)

Table 19. Global Pazopanib API Market Share by Players (2020-2025)

Table 20. Global Top Pazopanib API Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pazopanib API as of 2024)

Table 21. Ranking of Global Top Pazopanib API Companies by Revenue (US$ Million) in 2024

Table 22. Global 5 Largest Players Market Share by Pazopanib API Revenue (CR5 and HHI) & (2020-2025)

Table 23. Global Key Players of Pazopanib API, Headquarters and Area Served

Table 24. Global Key Players of Pazopanib API, Product and Application

Table 25. Global Key Players of Pazopanib API, Date of Enter into This Industry

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. North America Pazopanib API Revenue by Company (2020-2025) & (US$ Million)

Table 28. North America Pazopanib API Revenue Market Share by Company (2020-2025)

Table 29. North America Pazopanib API Market Size by Type (2020-2025) & (US$ Million)

Table 30. North America Pazopanib API Market Size by Application (2020-2025) & (US$ Million)

Table 31. Europe Pazopanib API Revenue by Company (2020-2025) & (US$ Million)

Table 32. Europe Pazopanib API Revenue Market Share by Company (2020-2025)

Table 33. Europe Pazopanib API Market Size by Type (2020-2025) & (US$ Million)

Table 34. Europe Pazopanib API Market Size by Application (2020-2025) & (US$ Million)

Table 35. Asia-Pacific Pazopanib API Revenue by Company (2020-2025) & (US$ Million)

Table 36. Asia-Pacific Pazopanib API Revenue Market Share by Company (2020-2025)

Table 37. Asia-Pacific Pazopanib API Market Size by Type (2020-2025) & (US$ Million)

Table 38. Asia-Pacific Pazopanib API Market Size by Application (2020-2025) & (US$ Million)

Table 39. Latin America Pazopanib API Revenue by Company (2020-2025) & (US$ Million)

Table 40. Latin America Pazopanib API Revenue Market Share by Company (2020-2025)

Table 41. Latin America Pazopanib API Market Size by Type (2020-2025) & (US$ Million)

Table 42. Latin America Pazopanib API Market Size by Application (2020-2025) & (US$ Million)

Table 43. Middle East & Africa Pazopanib API Revenue by Company (2020-2025) & (US$ Million)

Table 44. Middle East & Africa Pazopanib API Revenue Market Share by Company (2020-2025)

Table 45. Middle East & Africa Pazopanib API Market Size by Type (2020-2025) & (US$ Million)

Table 46. Middle East & Africa Pazopanib API Market Size by Application (2020-2025) & (US$ Million)

Table 47. Tecoland Company Details

Table 48. Tecoland Business Overview

Table 49. Tecoland Pazopanib API Product

Table 50. Tecoland Revenue in Pazopanib API Business (2020-2025) & (US$ Million)

Table 51. Tecoland Recent Development

Table 52. FCDA Company Details

Table 53. FCDA Business Overview

Table 54. FCDA Pazopanib API Product

Table 55. FCDA Revenue in Pazopanib API Business (2020-2025) & (US$ Million)

Table 56. FCDA Recent Development

Table 57. BIOBERRY Company Details

Table 58. BIOBERRY Business Overview

Table 59. BIOBERRY Pazopanib API Product

Table 60. BIOBERRY Revenue in Pazopanib API Business (2020-2025) & (US$ Million)

Table 61. BIOBERRY Recent Development

Table 62. Abcr Company Details

Table 63. Abcr Business Overview

Table 64. Abcr Pazopanib API Product

Table 65. Abcr Revenue in Pazopanib API Business (2020-2025) & (US$ Million)

Table 66. Abcr Recent Development

Table 67. Dr. Reddys Laboratories Company Details

Table 68. Dr. Reddys Laboratories Business Overview

Table 69. Dr. Reddys Laboratories Pazopanib API Product

Table 70. Dr. Reddys Laboratories Revenue in Pazopanib API Business (2020-2025) & (US$ Million)

Table 71. Dr. Reddys Laboratories Recent Development

Table 72. Pharmaffiliates Company Details

Table 73. Pharmaffiliates Business Overview

Table 74. Pharmaffiliates Pazopanib API Product

Table 75. Pharmaffiliates Revenue in Pazopanib API Business (2020-2025) & (US$ Million)

Table 76. Pharmaffiliates Recent Development

Table 77. Jigs Chemical Limited Company Details

Table 78. Jigs Chemical Limited Business Overview

Table 79. Jigs Chemical Limited Pazopanib API Product

Table 80. Jigs Chemical Limited Revenue in Pazopanib API Business (2020-2025) & (US$ Million)

Table 81. Jigs Chemical Limited Recent Development

Table 82. MuseChem Company Details

Table 83. MuseChem Business Overview

Table 84. MuseChem Pazopanib API Product

Table 85. MuseChem Revenue in Pazopanib API Business (2020-2025) & (US$ Million)

Table 86. MuseChem Recent Development

Table 87. Hairuichem Company Details

Table 88. Hairuichem Business Overview

Table 89. Hairuichem Pazopanib API Product

Table 90. Hairuichem Revenue in Pazopanib API Business (2020-2025) & (US$ Million)

Table 91. Hairuichem Recent Development

Table 92. AlchemyPharm Company Details

Table 93. AlchemyPharm Business Overview

Table 94. AlchemyPharm Pazopanib API Product

Table 95. AlchemyPharm Revenue in Pazopanib API Business (2020-2025) & (US$ Million)

Table 96. AlchemyPharm Recent Development

Table 97. Wuhan Fortuna Chemical Company Details

Table 98. Wuhan Fortuna Chemical Business Overview

Table 99. Wuhan Fortuna Chemical Pazopanib API Product

Table 100. Wuhan Fortuna Chemical Revenue in Pazopanib API Business (2020-2025) & (US$ Million)

Table 101. Wuhan Fortuna Chemical Recent Development

Table 102. Shanghai Pharmaceutical Group Co Company Details

Table 103. Shanghai Pharmaceutical Group Co Business Overview

Table 104. Shanghai Pharmaceutical Group Co Pazopanib API Product

Table 105. Shanghai Pharmaceutical Group Co Revenue in Pazopanib API Business (2020-2025) & (US$ Million)

Table 106. Shanghai Pharmaceutical Group Co Recent Development

Table 107. Shijiazhuang Dingmin Pharmaceutical Sciences Company Details

Table 108. Shijiazhuang Dingmin Pharmaceutical Sciences Business Overview

Table 109. Shijiazhuang Dingmin Pharmaceutical Sciences Pazopanib API Product

Table 110. Shijiazhuang Dingmin Pharmaceutical Sciences Revenue in Pazopanib API Business (2020-2025) & (US$ Million)

Table 111. Shijiazhuang Dingmin Pharmaceutical Sciences Recent Development

Table 112. CR Pharmaceutical Group Company Details

Table 113. CR Pharmaceutical Group Business Overview

Table 114. CR Pharmaceutical Group Pazopanib API Product

Table 115. CR Pharmaceutical Group Revenue in Pazopanib API Business (2020-2025) & (US$ Million)

Table 116. CR Pharmaceutical Group Recent Development

Table 117. Guangzhou Baiyunshan Pharmaceutical Group Company Details

Table 118. Guangzhou Baiyunshan Pharmaceutical Group Business Overview

Table 119. Guangzhou Baiyunshan Pharmaceutical Group Pazopanib API Product

Table 120. Guangzhou Baiyunshan Pharmaceutical Group Revenue in Pazopanib API Business (2020-2025) & (US$ Million)

Table 121. Guangzhou Baiyunshan Pharmaceutical Group Recent Development

Table 122. Pazopanib API Market Trends

Table 123. Pazopanib API Market Drivers

Table 124. Pazopanib API Market Challenges

Table 125. Pazopanib API Market Restraints

Table 126. Research Programs/Design for This Report

Table 127. Key Data Information from Secondary Sources

Table 128. Key Data Information from Primary Sources

List of Figures

Figure 1. Pazopanib API Product Picture

Figure 2. Global Pazopanib API Market Share by Type: 2024 VS 2031

Figure 3. Min Purity Less Than 98% Features

Figure 4. Min Purity 98%-99% Features

Figure 5. Min Purity More Than 99% Features

Figure 6. Global Pazopanib API Market Share by Application: 2024 VS 2031

Figure 7. Research

Figure 8. Pharmaceutical

Figure 9. Others

Figure 10. Pazopanib API Report Years Considered

Figure 11. Global Pazopanib API Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 12. Global Pazopanib API Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Pazopanib API Revenue Market Share by Region: 2020 VS 2024

Figure 14. North America Pazopanib API Revenue (US$ Million) Growth Rate (2020-2031)

Figure 15. Europe Pazopanib API Revenue (US$ Million) Growth Rate (2020-2031)

Figure 16. Asia-Pacific Pazopanib API Revenue (US$ Million) Growth Rate (2020-2031)

Figure 17. Latin America Pazopanib API Revenue (US$ Million) Growth Rate (2020-2031)

Figure 18. Middle East & Africa Pazopanib API Revenue (US$ Million) Growth Rate (2020-2031)

Figure 19. Global Pazopanib API Market Share by Players in 2024

Figure 20. Global Top Pazopanib API Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pazopanib API as of 2024)

Figure 21. The Top 10 and 5 Players Market Share by Pazopanib API Revenue in 2024

Figure 22. North America Pazopanib API Market Share by Type (2020-2025)

Figure 23. North America Pazopanib API Market Share by Application (2020-2025)

Figure 24. Europe Pazopanib API Market Share by Type (2020-2025)

Figure 25. Europe Pazopanib API Market Share by Application (2020-2025)

Figure 26. Asia-Pacific Pazopanib API Market Share by Type (2020-2025)

Figure 27. Asia-Pacific Pazopanib API Market Share by Application (2020-2025)

Figure 28. Latin America Pazopanib API Market Share by Type (2020-2025)

Figure 29. Latin America Pazopanib API Market Share by Application (2020-2025)

Figure 30. Middle East & Africa Pazopanib API Market Share by Type (2020-2025)

Figure 31. Middle East & Africa Pazopanib API Market Share by Application (2020-2025)

Figure 32. Tecoland Revenue Growth Rate in Pazopanib API Business (2020-2025)

Figure 33. FCDA Revenue Growth Rate in Pazopanib API Business (2020-2025)

Figure 34. BIOBERRY Revenue Growth Rate in Pazopanib API Business (2020-2025)

Figure 35. Abcr Revenue Growth Rate in Pazopanib API Business (2020-2025)

Figure 36. Dr. Reddys Laboratories Revenue Growth Rate in Pazopanib API Business (2020-2025)

Figure 37. Pharmaffiliates Revenue Growth Rate in Pazopanib API Business (2020-2025)

Figure 38. Jigs Chemical Limited Revenue Growth Rate in Pazopanib API Business (2020-2025)

Figure 39. MuseChem Revenue Growth Rate in Pazopanib API Business (2020-2025)

Figure 40. Hairuichem Revenue Growth Rate in Pazopanib API Business (2020-2025)

Figure 41. AlchemyPharm Revenue Growth Rate in Pazopanib API Business (2020-2025)

Figure 42. Wuhan Fortuna Chemical Revenue Growth Rate in Pazopanib API Business (2020-2025)

Figure 43. Shanghai Pharmaceutical Group Co Revenue Growth Rate in Pazopanib API Business (2020-2025)

Figure 44. Shijiazhuang Dingmin Pharmaceutical Sciences Revenue Growth Rate in Pazopanib API Business (2020-2025)

Figure 45. CR Pharmaceutical Group Revenue Growth Rate in Pazopanib API Business (2020-2025)

Figure 46. Guangzhou Baiyunshan Pharmaceutical Group Revenue Growth Rate in Pazopanib API Business (2020-2025)

Figure 47. Bottom-up and Top-down Approaches for This Report

Figure 48. Data Triangulation

Figure 49. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

What was the global market size of Pazopanib API in 2025? zhanKai

The global market size of Pazopanib API in 2025 was 1618 Million USD.

What is the annual compound growth rate of the global Pazopanib API market size from 2025 to 2031? shouQi

Which region is expected to have the highest market share? shouQi

What was the global market size of Pazopanib API in 2031? shouQi

Which companies rank high in the global Pazopanib API market? shouQi

Related Reports

Pazopanib API - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Pazopanib API was estimated to be worth US$ 1618 million in 2025 and is projected to reach US$ 2734 million, growing at a CAGR of 7.9% from 2026 to 2032.
Published Date: 2026-06-16
Pages: 118
USD 3950.00
(Single User License)
Global Pazopanib API Market Research Report 2026
The global Pazopanib API market was valued at US$ 1618 million in 2025 and is anticipated to reach US$ 2734 million by 2032, at a CAGR of 7.9% from 2026 to 2032.
Published Date: 2026-04-18
Pages: 112
USD 2900.00
(Single User License)
Global Pazopanib API Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Pazopanib API market is projected to grow from US$ 1510 million in 2024 to US$ 2553 million by 2031, at a CAGR of 7.9% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-11-09
Pages: 131
USD 4900.00
(Single User License)
Pazopanib API- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Pazopanib API was estimated to be worth US$ 1510 million in 2024 and is forecast to a readjusted size of US$ 2553 million by 2031 with a CAGR of 7.9% during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 113
USD 3950.00
(Single User License)
Global Pazopanib API Market Research Report 2025
The global market for Pazopanib API was valued at US$ 1510 million in the year 2024 and is projected to reach a revised size of US$ 2553 million by 2031, growing at a CAGR of 7.9% during the forecast period.
Published Date: 2025-01-16
Pages: 84
USD 2900.00
(Single User License)
Global Pazopanib API Market Insights, Forecast to 2030
Pazopanib is an anticancer medication that belongs to the class of drugs known as kinase inhibitors. It is primarily used for the treatment of advanced renal cell carcinoma (kidney cancer) and soft tissue sarcoma.
Published Date: 2024-04-15
Pages: 115
USD 4900.00
(Single User License)
Global Pazopanib API Market Research Report 2024
Pazopanib is an anticancer medication that belongs to the class of drugs known as kinase inhibitors. It is primarily used for the treatment of advanced renal cell carcinoma (kidney cancer) and soft tissue sarcoma.
Published Date: 2024-02-07
Pages: 93
USD 2900.00
(Single User License)
Pazopanib API - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Pazopanib is an anticancer medication that belongs to the class of drugs known as kinase inhibitors. It is primarily used for the treatment of advanced renal cell carcinoma (kidney cancer) and soft tissue sarcoma.
Published Date: 2024-01-15
Pages: 128
USD 3950.00
(Single User License)

Pazopanib API - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Pazopanib API was estimated to be worth US$ 1618 million in 2025 and is projected to reach US$ 2734 million, growing at a CAGR of 7.9% from 2026 to 2032.
Published: 2026-06-16
Pages: 118
USD 3950.00 (Single User License)
Global Pazopanib API Market Research Report 2026
The global Pazopanib API market was valued at US$ 1618 million in 2025 and is anticipated to reach US$ 2734 million by 2032, at a CAGR of 7.9% from 2026 to 2032.
Published: 2026-04-18
Pages: 112
USD 2900.00 (Single User License)
Global Pazopanib API Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Pazopanib API market is projected to grow from US$ 1510 million in 2024 to US$ 2553 million by 2031, at a CAGR of 7.9% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-11-09
Pages: 131
USD 4900.00 (Single User License)
Pazopanib API- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Pazopanib API was estimated to be worth US$ 1510 million in 2024 and is forecast to a readjusted size of US$ 2553 million by 2031 with a CAGR of 7.9% during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 113
USD 3950.00 (Single User License)
Global Pazopanib API Market Research Report 2025
The global market for Pazopanib API was valued at US$ 1510 million in the year 2024 and is projected to reach a revised size of US$ 2553 million by 2031, growing at a CAGR of 7.9% during the forecast period.
Published: 2025-01-16
Pages: 84
USD 2900.00 (Single User License)
Global Pazopanib API Market Insights, Forecast to 2030
Pazopanib is an anticancer medication that belongs to the class of drugs known as kinase inhibitors. It is primarily used for the treatment of advanced renal cell carcinoma (kidney cancer) and soft tissue sarcoma.
Published: 2024-04-15
Pages: 115
USD 4900.00 (Single User License)
Global Pazopanib API Market Research Report 2024
Pazopanib is an anticancer medication that belongs to the class of drugs known as kinase inhibitors. It is primarily used for the treatment of advanced renal cell carcinoma (kidney cancer) and soft tissue sarcoma.
Published: 2024-02-07
Pages: 93
USD 2900.00 (Single User License)
Pazopanib API - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Pazopanib is an anticancer medication that belongs to the class of drugs known as kinase inhibitors. It is primarily used for the treatment of advanced renal cell carcinoma (kidney cancer) and soft tissue sarcoma.
Published: 2024-01-15
Pages: 128
USD 3950.00 (Single User License)